In a phase I/II study of the anti-CD19 CAR T-cell therapy tisagenlecleucel in 75 pediatric and young adult patients with CD19+ relapsed/refractory ALL (ELIANA trial), the overall remission rate within 3 months was 81%, with event-free survival and overall survival of 73% and 90% at 6 months and 50% and 76% at 12 months, respectively. Here, CD19 is linked to acute lymphoblastic leukemia.